MDxHealth S.A. is a commercial-stage precision diagnostics company that... MDxHealth S.A. is a commercial-stage precision diagnostics company that delivers urological solutions across the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union, and other international markets. They offer innovative genomic testing solutions for prostate cancer, notably the non-invasive SelectMDx urine test and the epigenetic ConfirmMDx test. These advanced tools assist physicians in identifying clinically significant prostate cancer, thus minimizing the need for invasive procedures and their associated complications. Founded in 2003 as OncoMethylome Sciences SA, the company adopted its current name, MDxHealth SA, in October 2010 and is headquartered in Herstal, Belgium.
